v3.26.1
Revenue Recognition (Tables)
 6 Months Ended
Jun. 30, 2026
Revenue from Contract with Customer [Abstract]  
Schedule of Timing of Revenue Recognition
The following table illustrates the timing of the Company’s revenue recognition patterns:
Three Months Ended June 30,Six Months Ended June 30,
2026202520262025
Software products and services – point in time15.8 %29.4 %20.0 %36.5 %
Software products and services – over time39.5 36.4 38.0 34.4 
Drug Discovery – point in time17.0 5.5 8.5 3.7 
Drug Discovery – over time22.0 20.0 30.5 17.4 
Contribution – point in time3.4 — 1.7 — 
Contribution – over time2.3 8.7 1.3 8.0 
Schedule of Revenue Recognized from the Sources of Software Products and Services Revenue
The following table presents the revenue recognized from the sources of software products and services revenue:
Three Months Ended June 30,Six Months Ended June 30,
2026202520262025
On-premise software$9,297 $15,743 $23,477 $41,167 
Hosted software15,150 11,128 27,230 22,000 
Software maintenance4,878 6,778 11,540 13,573 
Professional services3,219 2,382 5,857 4,263 
Total software revenue$32,544 $36,031 $68,104 $81,003 
The following table presents the revenue recognized from the sources of contribution revenue:
Three Months Ended June 30,Six Months Ended June 30,
2026202520262025
Software contribution$2,921 $4,513 $2,921 $8,357 
Drug discovery contribution438 275 586 774
Total contribution revenue$3,359 $4,788 $3,507 $9,131 
Schedule of Contract Balances
Contract balances were as follows:
As of June 30, 2026As of December 31, 2025
Contract assets$19,514 $19,698 
Deferred revenue, short-term:
Software products and services52,310 66,695 
Drug discovery48,322 46,027 
Contribution4,141 131 
Deferred revenue, long-term:
Software products and services4,303 7,333 
Drug discovery40,849 71,544 
Contribution— — 
Remaining performance obligations were as follows:
As of June 30, 2026As of December 31, 2025
Deferred revenueTotalTotal
Software products and services$56,613 $74,028 
Drug discovery89,171 117,571 
Contribution4,141 131 
Total deferred revenue149,925 191,730 
Backlog
Software products and services30,543 31,036 
Drug discovery8,598 17,100 
Contribution— — 
Total backlog39,141 48,136 
Remaining performance obligations
Software products and services87,156 105,064 
Drug discovery97,769 134,671 
Contribution4,141 131 
Total remaining performance obligations$189,066 $239,866